Novo Nordisk said on Thursday it agreed to buy Akero Therapeutics for up to $5.2 billion, giving the Danish drugmaker access to an experimental liver disease drug.
In this article
Novo Nordisk
said on Thursday it agreed to buy Akero Therapeutics
for up to $5.2 billion, giving the Danish drugmaker access to the U.S.-based company’s experimental liver disease drug.
The maker of blockbuster obesity drug Wegovy is pressing ahead with a sweeping restructuring in a bid to revive sales growth and fend off intense competition from U.S. rival Eli Lilly
Novo Nordisk is investing in a facility in Ireland as it expands its production capacities of the newly launched Wegovy pill, the…
Denmark's Novo Nordisk said on Thursday it has made an unsolicited bid for U.S. drug maker Metsera, after Pfizer last week made…
Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, type 2…
The firm was granted U.S. approval for the treatment of metabolic dysfunction-associated steatohepatitis in adults with moderate…
Sales slump especially in the US market as Wegovy’s grip on the obesity drug market loosens.
Growing competition from smaller players is tightening the race for market leaders Novo Nordisk and Eli Lilly as more weight loss…
